Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?

Sally H. Ibbotson, Ronan Valentine, Ross Hearn

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    Topical photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) or methyl aminolevulinate (MAL) is widely used in dermatology. It is commonly stated that MAL PDT is less painful than ALA PDT, although published data are conflicting. We report our experience of the use of ALA (4-6?h) (n?=?20) and MAL (3?h) (n?=?20) in 40 consecutive patients with Bowen's disease or superficial basal cell carcinoma, treated with PDT using an identical irradiation regime. Although there was a trend to higher pain scores with ALA PDT [visual analogue scale (VAS)score, median 4.50], this was not significantly different from that of MAL PDT (VAS score, median 3.55; P?=?0.98), nor considered to be clinically important. Importantly, both ALA and MAL PDT regimes were fairly well tolerated in this patient cohort, supporting the use of these prodrugs in dermatological PDT.
    Original languageEnglish
    Pages (from-to)272-273
    Number of pages2
    JournalPhotodermatology, Photoimmunology & Photomedicine
    Volume28
    Issue number5
    DOIs
    Publication statusPublished - Oct 2012

    Keywords

    • Bowen's Disease
    • Photosensitizing Agents
    • Humans
    • Photochemotherapy
    • Pain Measurement
    • Pain
    • Carcinoma, Basal Cell
    • Skin Neoplasms
    • Male
    • Administration, Topical
    • Aminolevulinic Acid

    Fingerprint Dive into the research topics of 'Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?'. Together they form a unique fingerprint.

    Cite this